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Cholangiocarcinoma
Nataliya Razumilava, Gregory J Gores
Cholangiocarcinoma represents a diverse group of epithelial cancers united by late diagnosis and poor outcomes. 
Speciﬁ c diagnostic and therapeutic approaches are undertaken for cholangiocarcinomas of diﬀ erent anatomical 
locations (intrahepatic, perihilar, and distal). Mixed hepatocellular cholangiocarcinomas have emerged as a distinct 
subtype of primary liver cancer. Clinicians need to be aware of intrahepatic cholangiocarcinomas arising in cirrhosis 
and properly assess liver masses in this setting for cholangiocarcinoma. Management of biliary obstruction is 
obligatory in perihilar cholangiocarcinoma, and advanced cytological tests such as ﬂ uorescence in-situ hybridisation 
for aneusomy are helpful in the diagnosis. Liver transplantation is a curative option for selected patients with perihilar 
but not with intrahepatic or distal cholangiocarcinoma. International eﬀ orts of clinicians and scientists are helping to 
identify the genetic drivers of cholangiocarcinoma progression, which will unveil early diagnostic markers and direct 
development of individualised therapies.
Introduction
Cholangiocarcinoma is an epithelial cell malignancy 
arising from varying locations within the biliary tree 
showing markers of cholangiocyte diﬀ erentiation. The 
most contemporary classiﬁ cation based on anatomical 
location includes intrahepatic, perihilar, and distal 
cholangiocarcinoma. Intrahepatic cholangiocarcinoma is 
deﬁ ned as a cholangiocarcinoma located proximally to 
the second degree bile ducts (proximal and distal refers 
to the direction of bile ﬂ ow such that the intrahepatic bile 
ducts are proximal to the common bile duct); within the 
liver, perihilar cholangiocarcinoma is localised to the 
area between the second degree bile ducts and the 
insertion of the cystic duct into the common bile duct; 
whereas distal cholangiocarcinoma is conﬁ ned to the 
area between the origin of the cystic duct and ampulla of 
Vater.1 Most cholangiocarcinomas are well, moderately, 
and poorly diﬀ erentiated adenocarcinomas with other 
histological subtypes encountered rarely.2,3 Surgical 
treatment is the preferred option for all subtypes, but, 
when contemplated, involvement of the vascular 
structures and lymph nodes needs to be considered. The 
highly desmoplastic nature of cholangiocarcinoma, its 
extensive support by a rich tumour microenvironment, 
and profound genetic heterogeneity, all contribute to its 
therapeutic resistance. Although surgery and curative 
liver transplantation are options for selected patients 
with perihilar cholangiocarcinoma, 5-year survival rates 
are very low. The chemotherapy regimen of gemcitabine 
and cisplatin is often used for inoperable disease. 
Locoregional therapies are used for intrahepatic 
cholangiocarcinoma, but conclusive evidence for eﬃ  cacy 
is lacking. Understanding of cholangiocarcinoma 
biology, the oncogenic landscape of this disease, and its 
complex interaction with the tumour microenvironment 
could lead to optimum therapies with improvement in 
patient survival. In view of much recent interest in this 
disease, a review of recent medical advances for 
cholangiocarcinoma is both timely and topical. In this 
Seminar we focus mainly on intrahepatic and perihilar 
cholangiocarcinoma because progress has predominantly 
occurred in these subtypes (panel).
Epidemiology and risk factors
Perihilar disease represents about 50%, distal disease 
40%, and intrahepatic disease less than 10% of 
cholangiocarcinoma cases.4 Mixed hepatocellular-
cholangiocellular carcinomas, also called combined 
hepatocellular-cholangiocellular carcinomas according to 
the WHO classiﬁ cation, were only recently acknowledged 
as a distinct subtype of cholangiocarcinoma.2,5,6 According 
to scarce reports,5,7 mixed hepatocellular-cholangiocellular 
carcinomas represent less than 1% of all liver cancers. 
The incidence of intrahepatic cholangiocarcinoma seems 
to be increasing in many western countries, although this 
pattern is not universal.8,9 Age-adjusted rates of 
cholangiocarcinoma are reported to be highest in 
Hispanic and Asian populations (2·8–3·3 per 100 000) 
and lowest in non-Hispanic white people and black 
people (both 2·1 per 100 000).10–12 The disease has a slight 
male predominance (1·2–1·5 per 100 000 vs one per 
100 000 population),12 with the exception of the female 
Hispanic population in whom intrahepatic cholangio-
carcinoma rates are increased (1·5 per 100 000) compared 
with the male population (0·9 per 100 000).12 
Cholangiocarcinoma is unusual in children. Cumulative 
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Search strategy and selection criteria
We searched PubMed for articles in English using the 
combination of keywords “cholangiocarcinoma” with 
“carcinogenesis”, “progression”, “pathophysiology”, “molecular 
pathogenesis”, “genetics”, “diagnosis”, “markers”, “imaging”, 
“treatment”, “chemotherapy”, “surgery”, “stent”, and 
“radiation”. The search included articles published from Jan 1, 
1985, to May 31, 2013, and preferences were given to highly 
cited publications, articles published in the past 3 years, and 
articles published since the previous Seminar about 
cholangiocarcinoma in The Lancet in 2005. Owing to the very 
small number of randomised controlled trials in 
cholangiocarcinoma and limited space, review articles and 
centre experiences comprise a large number of references in 
this Seminar.
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cholangiocarcinoma mortality rates have increased by 
39% because of increased disease incidence.12 Mortality 
rates are higher in men and boys (1·9 per 100 000) than in 
women and girls (1·5 per 100 000). Mortality rates from 
intrahepatic cholangiocarcinoma are highest in American 
Indian and Alaska Native groups (1·3 per 100 000) and 
Asian populations (1·4 per 100 000) and lowest in white 
people (0·8 per 100 000) and black people (0·7 per 100 000).9 
Both increased recognition and incidence have 
contributed to rising interest in this cancer.13
Most cholangiocarcinomas arise de novo, and no risk 
factors are identiﬁ ed. Recently, cirrhosis and viral 
hepatitis C and B have been recognised as risk factors for 
cholangiocarcinoma, especially intrahepatic disease. The 
contribution of hepatitis C and hepatitis B in tumour 
development diﬀ ers in western countries, where 
hepatitis C is more prevalent, versus Asian countries, 
where hepatitis B is endemic. In studies from the USA 
and Europe,14–17 hepatitis C was shown to be a risk factor 
for cholangiocarcinoma with the strongest association 
for intrahepatic cholangiocarcinoma. Studies from South 
Korea and China18–20 have shown more consistently 
hepatitis B as a risk factor for intrahepatic cholangio-
carcinoma; a Japanese study conﬁ rmed ﬁ ndings from 
western countries where intrahepatic cholangiocarcinoma 
association was stronger with hepatitis C exposure than 
with hepatitis B.21 Association with cirrhosis of diﬀ erent 
causes was identiﬁ ed in almost all of these studies. 
Pathogenically, release of inﬂ ammatory cytokines, cell 
death coupled to increases in cell proliferation, as well as 
changes in the liver in ﬁ brosis favour tumorigenesis. 
However, the presence of cirrhosis is not uniformly 
shown in all patients with viral hepatitis who develop 
cholangiocarcinoma.20 A meta-analysis22 of several case-
control studies on risk factors for intrahepatic 
cholangiocarcinoma showed the following associations: 
cirrhosis had a combined odds ratio (OR) of 22·92 
(95% CI 18·24–28·79), hepatitis C of 4·84 (2·41–9·71), 
and hepatitis B of 5·10 (2·91–8·95).
There is a well established association between 
primary sclerosing cholangitis, marked by chronic 
inﬂ ammation with liver injury and likely proliferation 
of the progenitor cells, and cholangiocarcinoma, 
especially perihilar disease. The lifetime incidence of 
cholangiocarcinoma in this patient population ranges 
between 5% and 10%.23–26 About 50% of patients with 
primary sclerosing cholangitis who develop 
cholangiocarcinoma are diagnosed with cholangio-
carcinoma within 24 months of diagnosis of primary 
sclerosing cholangitis.23,27 The risk of cholangio-
carcinoma is lower 2–10 years after the diagnosis of 
primary sclerosing cholangitis (7%).26 The mean age of 
cholangiocarcinoma diagnosis in patients with primary 
sclerosing cholangitis is the fourth decade of life23,28 
compared with the seventh decade in the general 
population.10,17 Although various risk factors for 
cholangiocarcinoma in primary sclerosing cholangitis 
have been reported, none are suﬃ  cient to guide risk 
stratiﬁ cation for disease surveillance. Guidelines for 
cholangiocarcinoma surveillance in patients with 
primary sclerosing cholangitis have been published.25,29,30
Early age at diagnosis is also noted in patients with bile 
duct cystic disorders, including Caroli’s disease.10,14,31 These 
patients develop cholangiocarcinoma at a mean age of 
32 years with lifetime incidence ranging from 6% to 30%.18 
Southeast Asia has a very high incidence (113 per 100 000)10 
of cholangiocarcinoma that is due to high prevalence of 
hepatobiliary ﬂ ukes, Opisthorchis viverrini and Clonorchis 
sinensis, which are risk factors for cholangiocarcinoma.32,33 
This risk is probably increased by environmental and 
genetic factors.34 Hepatolithiasis, in which 7% of patients 
develop intrahepatic cholangiocarcinoma,2,35 and biliary-
Panel: Key messages
• Cholangiocarcinoma is anatomically classiﬁ ed as 
intrahepatic, perihilar, and distal
• Mixed hepatocellular-cholangiocellular carcinoma is a 
subtype of intrahepatic neoplasm that shows markers of 
hepatocellular carcinoma and cholangiocarcinoma 
diﬀ erentiation simultaneously and is associated with 
worse prognosis compared with hepatocellular carcinoma
• Cirrhosis and hepatitis B and C are recently identiﬁ ed risk 
factors for intrahepatic cholangiocarcinoma
• All intrahepatic lesions in cirrhosis should be investigated to 
rule out the possibility of intrahepatic cholangiocarcinoma
• Fluorescence in-situ hybridisation improves performance 
of cytological evaluation of biliary brushings for the 
diagnosis of perihilar cholangiocarcinoma
• Proliferative and inﬂ ammatory gene signature classes have 
been described in intrahepatic cholangiocarcinoma; FGFR2 
gene fusion and IDH1 and IDH2 mutations are newly 
identiﬁ ed targetable derangements in cholangiocarcinoma
• Surgical resection is a ﬁ rst-line therapy in patients with 
intrahepatic or perihilar cholangiocarcinoma who are 
good surgical candidates and have no evidence of disease 
progression beyond regional lymph nodes
• Surgical techniques for perihilar cholangiocarcinoma are 
improved by extended resection, portal vein 
embolisation, and associating liver partition and portal 
vein ligation for staged hepatectomy
• The best outcomes are observed in highly selected patients 
with perihilar cholangiocarcinoma treated with liver 
transplantation coupled with neoadjuvant chemoradiation
• Locoregional therapies can be considered for intrahepatic 
cholangiocarcinoma
• Gemcitabine and cisplatin combination is an acceptable 
standard of practice for advanced intrahepatic 
cholangiocarcinoma; for perihilar disease the eﬀ ectiveness 
remains less proven
• Elucidation of cholangiocarcinoma molecular pathogenesis 
could guide early diagnosis, prevention, and individualised 
treatment
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enteric drainage, predisposing patients to enteric bacteria 
bile duct colonisation and infections,36 are additional risk 
factors for cholangiocarcinoma. Several genetic 
polymorphisms have been identiﬁ ed that increase risk of 
development of cholangiocarcinoma. The genes implicated 
as risk factors can be classiﬁ ed into those encoding 
proteins participating in cell DNA repair (MTHFR, TYMS, 
GSTO1, and XRCC1), cellular protection against toxins 
(ABCC2, CYP1A2, and NAT2), or immunological 
surveillance (KLRK1, MICA, and PTGS2).10 The results 
from studies on the role of alcohol and smoking exposure 
have been inconsistent.10,22 The metabolic syndrome 
was associated with an increased risk of intra-
hepatic cholangiocarcinoma in the Surveillance and 
Epidemiology Results database analysis (OR 1·6, 
1·32–1·83, p<0·0001).37 Consistent with these observations, 
the meta-analysis22 of US and Danish studies identiﬁ ed an 
association of intra hepatic cholangiocarcinoma with 
diabetes with an OR of 1·89 (95% CI 1·74–2·07) and 
obesity with an OR of 1·56 (1·26–1·94). Although obesity 
is a biologically plausible risk factor for cholangiocarcinoma 
development, too few data are available to deﬁ nitely 
establish an association at this time.10,22
Molecular pathogenesis
The era of individualised medicine and targeted therapies 
needs improved understanding of tumour biology and 
molecular pathogenesis. Carcinogenesis involves speciﬁ c 
cell genome derangements.38 The genetic pathways 
contributing to the selective growth advantage of cancer 
cells can be organised into those governing cell fate and 
diﬀ erentiation, proliferation, cell survival, and 
maintenance of genome integrity. Contemporary research 
techniques are allowing identiﬁ cation of several of these 
genetic changes in cholangiocarcinoma.39 However, 
misclassiﬁ cation of perihilar cholangio carcinoma as 
intrahepatic cholangiocarcinoma in the early studies 
should be considered during interpretation of retrospective 
studies on molecular proﬁ ling. Further knowledge could 
identify driver mutations that can be successfully targeted 
resulting in improved patient survival. Unfortunately, 
curative therapies have been diﬃ  cult to develop for solid 
tumours because of the extreme genetic heterogeneity 
between patients and rapid development of therapeutic 
resistance as the tumour genetically evolves. Several 
oncogenic pathways and drugs targeting these pathways 
have been identiﬁ ed (table). Several studies identifying 
genetic changes in cholangiocarcinoma have been 
published, but most of the data generated from the single 
studies need further validation. Hopefully, personalised or 
precision medicine is in the near future for the treatment 
of cholangiocarcinoma (ﬁ gure 1).
Cell survival signalling pathways
The Ras-MAPK pathway is one of the main signalling 
networks in cholangiocarcinoma biology and was reported 
in several studies. For example, Sia and colleagues40 used 
an integrative molecular analysis technique and correlated 
identiﬁ ed gene signatures with clinicopathological traits 
and patient outcomes for 119 cases of intrahepatic 
cholangiocarcinoma. The group described two distinct 
gene signature classes: a proliferation class and an 
inﬂ ammatory class. The proliferation class (62% of cases) 
was associated with copy number variations in several 
oncogenes, including but not restricted to KRAS and 
BRAF, as well as in genes from RAS, MAPK, and MET 
signalling networks. The proteins encoded by these genes 
are part of the signalling network in which the RAS-RAF-
MEK-ERK signalling axis stimulates cell proliferation or 
the PI3K-AKT-mTOR signalling axis promotes cell survival. 
The inﬂ ammatory class showed activation of inﬂ ammatory 
pathways causing overexpression of cytokines and STAT3. 
The transcriptional factor STAT3 modulates cell growth 
and survival and has been implicated in carcinogenesis.41 
These gene classes, particularly the proliferation class, in 
intrahepatic cholangiocarcinoma overlapped with those 
previously identiﬁ ed in hepatocellular carcinoma in which 
cell-cycle dysregulation, transforming growth factor β 
(TGFβ)/Wnt activation, α-fetoprotein positivity, and 
cholangiocarcinoma-like and cluster A classes were 
associated with poor outcomes. This ﬁ nding implies cells 
of similar origin in both cancer subtypes or hepatocellular 
carcinoma cell dediﬀ erentiation towards an adeno-
carcinoma phenotype. These data also emphasise that not 
all cancers have a proliferative signature. Besides 
uncontrollable cell proliferation, neoplastic transformation 
can also be accomplished by evasion of apoptosis, 
facilitation of cell migration (ie, metastatic potential), 
resistance to hypoxia, and increased vascularisation.
In another study,42 transcriptome proﬁ ling in 
104 patients after cholangiocarcinoma resection in 
Europe, the USA, and Australia showed that KRAS 
Molecular inhibitors
EGFR (RAS, RAF, MEK, ERK/MAPK), 14% Erlotinib, cetuximab, irinotecan, panitumumab, 
lapatinib, sorafenib
VEGF, frequency unknown Sorafenib, bevacizumab, erlotinib, cediranib, 
vandetanib
Her2/neu, 8% Lapatinib
MET (PI3K, AKT, mTOR), 5% Onartuzumab, tivantinib, crizotinib
mTOR, frequency unknown Everolimus
MEK, frequency unknown Selumetinib, trametinib
AKT, 1% MK2206
NFκB, frequency unknown Bortezomib
PI3K/mTOR, 9% GDC-0980
PARP1/2, frequency unknown Veliparib
MET/ROS/ALK, frequency unknown Crizotinib
FGFR2 gene fusion, frequency unknown PD173074, pazopanib
IDH1 and IDH2, 10–23% of intrahepatic cholangiocarcinomas AGI-6780, AGI-5198
Table modiﬁ ed from Geynisman and colleagues.44
Table: Targetable cholangiocarcinoma signalling pathways with estimated frequency and corresponding 
molecular inhibitors
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mutations were associated with deregulation of 
epidermal growth factor (EGFR) and ERBB2 (also known 
as HER2) signalling network, which included MET. 
Derangement of genes participating in proteasomal 
activity was associated with poor prognosis. The 
therapeutic potential of tyrosine kinase inhibition in 
cholangiocarcinoma cell lines with activated EGFR and 
HER2 was also shown.42 Although EGFR might act as a 
hub for transmitting downstream signals to activate 
RAS-MAPK, JAK-STAT, and PI3K-AKT-mTOR path-
ways,43,44 the more likely situation is that cross-talk exists 
between various receptor tyrosine kinases.
206 somatic mutations were identiﬁ ed and examined 
with exome sequencing and comparison of eight liver-
ﬂ uke-associated cholangiocarcinoma and matched 
normal tissue specimens in a study from Singapore.45 
Among the common cancer-related genes, mutations in 
TP53 responsible for maintenance of genome integrity 
was most common (44%), followed by KRAS (17%), and 
SMAD4 (17%); SMAD4 contributes to the TGFβ 
signalling network, which is a key driver of metastatic 
cancer. Somatic mutations of genes involved in 
deactivation of histone modiﬁ ers, activation of G proteins, 
and loss of genome stability were present in 3·7–14·8% 
of cases in this study with many of the genes being newly 
implicated in oncogenesis (eg, KMT2C, ROBO2, RNF43, 
PEG3, and GNAS).45
Genetic changes in the tumour suppressive gene PTEN 
in combination with either activated AKT or mTOR were 
associated with poor patient outcomes in microarray 
analysis of 221 samples of extrahepatic cholangio-
carcinoma.46 However, the correlation between these 
genetic changes and good outcomes was reported in 
101 patients with intrahepatic cholangiocarcinoma in 
another study, in which mTOR and AKT activation was 
detected in more diﬀ erentiated tumours.47 Novel ﬁ broblast 
growth factor receptor 2 (FGFR2) rearrangements with 
gene fusion were identiﬁ ed in a subset of patients with 
cholangiocarcinoma and these mutations are targetable.48
Cell fate and diﬀ erentiation
Notch signalling is vital in cell fate determination and 
regulates biliary duct formation.49 Its involvement in 
cholangiocarcinoma biology was reported in several 
studies. Notch pathway activation was implicated in 
conversion of mature adult hepatocytes into precursors 
of intrahepatic cholangiocarcinoma in two preclinical 
models involving cell fate tracing techniques.20,50 These 
studies challenge the theory that cholangiocarcinoma 
cells are derived from cholangiocytes, peribiliary 
glandular cells, or hepatic progenitor cells. They also 
emphasise the plasticity of liver cells regarding their 
diﬀ erentiated state, and draw attention to transcriptome 
studies identifying overlap in hepatocellular carcinoma 
and cholangiocarcinoma signatures.40 A study51 in an 
animal model of diethylnitrosamine-induced hepato-
cellular carcinoma carcinogenesis showed the role of 
constitutive Notch2 activation in the development of 
poorly diﬀ erentiated hepatocellular carcinoma with 
features of biliary epithelium (SOX9 positivity). These 
studies suggest that even diﬀ erentiated liver cell subtypes 
are plastic and dominance of underlying oncogenic 
Figure 1: Integrative approach to (A) diagnosis and (B) individualised medicine in cholangiocarcinoma
FISH=ﬂ uorescence in-situ hybridisation. SDS-PAGE=sodium dodecyl sulfate polyacrylamide gel electrophoresis.
Diagnosis of cholangiocarcinoma 
Precision therapy for cholangiocarcinoma 
Cancer driver pathways
Personalised targeted therapy
Diagnostic battery
Biological specimen: blood or bile/bile duct sampling 
Biological specimen: tumour sampling and blood DNA or RNA sequencing of the whole 
genome of the tumour and blood cells
Data gathering or storage
Bioinformatic analysis
Proteomics by mass spectrometry miRNA FISH Two-dimensional SDS-PAGE
FGFR2
fusion
Notch mTOREGFR METIDH Chromatin
modiﬁers
A
B
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pathways can dictate cell histological features with 
variable malignant phenotypes (eg, hepatocellular or 
cholangiocellular carcinomas). Figure 2 shows the 
potential cells of origin for cholangiocarcinoma.
Experimental studies have also shown an important 
role for the Hh survival signalling pathway in 
cholangiocarcinoma52 with pathway inhibition being 
tumour suppressive in several studies.53 The mechanisms 
vary from inhibition of transcriptional activation and 
migration, to inhibition of miRNA expression.53–55 
Interplay between Hh signalling and the myoﬁ broblast-
enriched cholangiocarcinoma microenvironment has 
also been identiﬁ ed: platelet-derived growth factor BB 
promotes tumour survival in an Hh-dependent manner 
in vitro and in an animal model.56
Isocitrate dehydrogenase (IDH) mutations and 
epigenetic changes
Genetic changes leading to survival advantages can also 
occur through epigenetic changes coupled to DNA 
coding changes. Hot-spot mutations of genes encoding 
IDH1 and IDH2 were recently reported by several groups 
to be fairly speciﬁ c to intrahepatic cholangiocarcinoma in 
various gastrointestinal and biliary cancers (10–23%).57–59 
These mutations are commonly identiﬁ ed in association 
with global DNA hypermethylation leading to multiple 
epigenetic changes.58 Identiﬁ cation of these new mutated 
genes is especially interesting because the product of 
enzymatic activity of IDH1 and IDH2, 2-hydroxyglutarate, 
can be detected in the serum and, therefore, potentially 
be used as a biomarker.60 Importantly, inhibition of IDH 
gain of function mutations has been reported, which 
reverses epigenetic methylation and promotes cancer cell 
diﬀ erentiation.61,62 Cholangiocarcinoma would be a 
candidate for treatment with these inhibitors.
Cytotoxic and targeted therapies
A pragmatic practice standard was established by the 
ABC-2 study,63 in which 410 patients with advanced 
biliary tract cancer were randomly assigned to receive 
either gemcitabine and cisplatin in combination or 
gemcitabine alone. Patients receiving combination 
therapy had a median overall survival (OS) of 
11·7 months versus 8·1 months in patients receiving 
gemcitabine alone (hazard ratio [HR] 0·64, 
95% CI 0·52–0·80).63 Patients with gallbladder cancer 
and intrahepatic cholangio carcinoma responded better 
to this regimen than did the rest of the trial population. 
The beneﬁ ts of the combination therapy are, however, 
small and the number of patients low compared with 
other oncological trials. Therefore, these results should 
not preclude development of head-to-head trials of 
gemcitabine plus cisplatin versus promising 
therapies.44,64 More precise therapy might provide 
improved eﬃ  cacy and safety proﬁ les, and several of the 
signalling pathways involved in cholangiocarcinoma 
biology are possible targets (table).44
The number of clinical trials with targeted therapy 
alone or in combination with traditional chemotherapy is 
expanding. The single open-label randomised phase 3 
trial65 with gemcitabine and oxaliplatin with or without 
erlotinib showed a small improvement in median 
progression-free survival in the subset of patients with 
cholangiocarcinoma receiving chemotherapy plus 
targeted therapy (5·9 months) versus chemotherapy 
alone (3·0 months; HR 0·73, 95% CI 0·53–1·00, 
p=0·049). Although sorafenib and lapatinib monotherapy 
was not eﬀ ective, the combination of gemcitabine and 
oxaliplatin with cetuximab or bevacizumab is promising.66 
Results of several phase 2 trials are pending. OS, instead 
of progression-free survival, should be the main endpoint 
in contemporary clinical trial designs.
Intrahepatic cholangiocarcinoma
Clinical classiﬁ cation and diagnosis
Intrahepatic cholangiocarcinoma can be classiﬁ ed 
morphologically by growth patterns as mass-forming, 
periductal-inﬁ ltrating, intraductal, superﬁ cial spreading, 
and undeﬁ ned subtypes.2,67–69 The superﬁ cial spreading 
and intraductal subtypes are associated with the best 
prognosis and periductal and mass-forming subtypes 
with the worst. Intrahepatic cholangiocarcinoma 
presents as a malignant mass lesion usually in a non-
cirrhotic liver. However, when an intrahepatic lesion is 
noted in an imaging study in the setting of cirrhosis, the 
next diagnostic step is the diﬀ erentiation between 
cholangiocarcinoma and hepatocellular carcinoma. 
Typical radiological features of cholangiocarcinoma 
include progressive contrast uptake throughout both 
arterial and venous phases of a cross-sectional imaging 
study.70 By contrast, hepatocellular carcinoma lesions are 
associated with hyperenhancement in the arterial phase 
and contrast washout in the venous phase of a contrast-
Figure 2: Potential cells of origin in intrahepatic cholangiocarcinoma
PV=portal vein. HA=hepatic artery. BD=bile duct. HC=hepatic cell.
Cholangiocarcinoma
Hepatocyte transdiﬀerentiation 
and transformation
Progenitor cell
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Seminar
www.thelancet.com   Vol 383   June 21, 2014 2173
enhanced imaging study. CT scan performance in 
intrahepatic cholangiocarcinoma was recently validated 
in a study71 in which intrahepatic lesions in patients with 
cirrhosis detected either on surveillance with ultrasound 
or incidentally (66% and 34%, respectively) were re-
assessed with a CT scan. All but one cholangiocarcinoma 
lesion showed typical heterogeneous contrast uptake due 
to a highly vascularised interface from peritumoural 
inﬂ ammation resulting in arterial enhancement of the 
tumour parenchymal margins, so-called rim enhance-
ment. However, these classic features of intrahepatic 
cholangiocarcinoma were present in only 70% of cases in 
another study.72
To further complicate this issue, liver cancer can contain 
both elements of cholangiocarcinoma and hepatocellular 
carcinoma in the same nodule, termed mixed 
hepatocellular-cholangiocellular carcinomas.5 Studies 
suggest that mixed hepatocellular-cholangio cellular 
carcinomas have a distinct appearance on cross-sectional 
imaging studies. A strong enhancing rim and irregular 
shape on gadoxetic acid-enhanced MRI favours mixed 
hepatocellular-cholangiocellular carcinoma, and lobulated 
shape, weak rim, and a target appearance favours a mass-
forming intrahepatic cholangio carcinoma.73 The target 
appearance can also help to diﬀ erentiate mixed 
hepatocellular-chol angio cellular carcinomas from atypical 
hypovascular hepatocellular carcinoma.74 The presence of 
liver capsule retraction and biliary dilatation in the vicinity 
of the intrahepatic lesion can also raise suspicion for a 
diagnosis of intrahepatic cholangiocarcinoma. A PET scan 
might be beneﬁ cial in assessment of metastatic disease,75 
but many cholangiocarcinomas are PET negative with ¹⁸F-
ﬂ uorodeoxyglucose.76 Contrast-enhanced ultrasound is 
associated with a very high misdiagnosis rate compared 
with MRI (52% vs 9%) and CT scans (52% vs 4%).77 Biopsy 
of the intrahepatic lesion is needed to diﬀ erentiate 
hepatocellular carcinoma from cholangiocarcinoma to 
diagnose intrahepatic chol angiocarcinoma, especially if 
imaging studies do not show classic signs of hepatocellular 
carcinoma or if the distinction will change management 
(ﬁ gure 3A).
Carbohydrate antigen 19-9 (CA 19-9) is a traditional 
serum biomarker used for cholangiocarcinoma 
diagnosis. In patients with primary sclerosing cholangitis 
the most reliable cutoﬀ  for intrahepatic chol-
angiocarcinoma is 129 U/mL, which provides sensitivity, 
speciﬁ city, and adjusted positive predictive values of 79%, 
98%, and 57%, respectively.78,79 However, more than 30% 
of patients with primary sclerosing cholangitis with a 
CA 19-9 value higher than 129 U/mL do not have 
cholangiocarcinoma on long-term follow up,80,81 and 
alternative causes for this increase, including bacterial 
cholangitis, should be considered. CA 19-9 concentrations 
higher than 1000 U/mL are consistent with advanced 
disease often involving the peritoneum.80–82 When 
interpreting serum CA 19-9 concentrations one should 
also note whether patients who are negative for Lewis 
antigen (7% of general population) have undetectable 
serum CA 19-9 concentrations.83 A better-performing 
biomarker is needed.
Surgical resection and liver transplantation
Recommendations for treatment take into consideration 
the patient’s surgical candidacy, biochemical 
characteristics, lesion size, presence of metastatic lesions, 
and vascular and lymphatic involvement. The tumour 
burden should be assessed with cross-sectional imaging 
Figure 3: Approach to management of (A) intrahepatic and (B) perihilar cholangiocarcinoma
HCC=hepatocellular carcinoma. CA 19-9=carbohydrate antigen 19-9. Reproduced with modiﬁ cations from 
reference 69 by permission of Elsevier.
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studies of the chest and abdomen and potentially biopsy 
of the lymph nodes, when lymph nodes are larger than 
2 cm. Curative surgical resection with negative tumour 
margins can be achieved in less than 30% of patients.4 
The median survival time by intention-to-treat analysis of 
lesions considered to be surgically resectable on imaging 
studies is 36 months84 Positive tumour margins, lymph 
node metastases, cirrhosis, especially advanced cirrhosis 
with Child-Pugh score beyond A, and presence of portal 
hypertension are associated with poor outcomes in 
surgical cohorts.4,84,85 Contemporary studies do not support 
the option of liver transplantation for intrahepatic 
cholangiocarcinoma unlike for selected patients with 
perihilar cholangiocarcinoma. Indeed, even patients with 
mixed hepatocellular-cholangiocellular carcinomas have 
1-year and 5-year cumulative risk of tumour recurrence of 
42% and 65%, respectively, after liver transplantation.86
Palliative treatment with locoregional therapies
Like hepatocellular carcinoma, intrahepatic cholangio-
carcinoma has a metastatic predilection for the liver and, 
therefore, locoregional therapy might be a reasonable 
palliative approach; the eﬀ ectiveness of this option, 
however, has not been evaluated in high-quality 
randomised studies. Limitations of radiofrequency 
ablation are low eﬀ ectiveness in lesions larger than 5 cm 
and technical complications in close proximity to the 
large vascular structures and liver capsule.87,88 Recurrence 
rates for intrahepatic cholangiocarcinoma are also quite 
high after radiofrequency ablation.87 Most studies 
examining transarterial chemoembolisation (TACE) are 
retrospective and do not use a standardised 
chemotherapeutic drug or schedule. However, data 
suggest acceptable tolerability and a potential survival 
beneﬁ t in patients receiving TACE (OS 12–15 months vs 
3·3 months in the best supportive care group).89–92 TACE 
with use of drug-eluting beads might have similar 
eﬀ ectiveness as systemic chemotherapy (OS 11·7 months 
and 11 months, respectively) and performs better than 
conventional TACE (OS 5·7 months).93 Safety and eﬃ  cacy 
of selective intra-arterial radiotherapy with radioactive 
⁹⁰Y in an adjuvant setting was recently reported.94 The 
group reported a median OS of 22 months with no major 
toxicity-related events. In another report, 1-year survival 
after ⁹⁰Y treatment was 56%.95 Contemporary stereotactic 
body radiotherapy in cholangiocarcinoma is associated 
with a high rate of treatment-related complications 
including acute radiation-induced liver dysfunction, 
biliary strictures, and gastrointestinal mucosa damage.96–98
Perihilar cholangiocarcinoma
Clinical classiﬁ cation and diagnosis
Perihilar cholangiocarcinomas are conﬁ ned to the larger 
bile ducts in the hepatic hilum and are classiﬁ ed on the 
basis of morphological growth appearance in mass-
forming exophytic and intraductal subtypes. Intraductal 
subtypes can be further subclassiﬁ ed as periductal 
inﬁ ltrating, the most common perihilar cholangio-
carcinoma subtype, in addition to mass, and nodular 
perihilar cholangiocarcinoma subtypes. Intraductal 
papillary neoplasms are often well diﬀ erentiated and have 
favourable prognosis, whereas presence of an invasive 
component predisposes to metastasis. The most recently 
described subtype is an intraductal tubulopapillary 
neoplasm, which has better prognosis than does exophytic 
perihilar cholangiocarcinoma.99 The acute onset of 
painless jaundice is a heralding presentation in 90% of 
patients with chol angiocarcinoma.3,100
Careful evaluation with cross-sectional imaging studies 
and endoscopic ultrasonography helps to delineate the 
tumour location, size, morphology, hepatic artery and 
portal vein involvement, volume of potential liver remnant, 
lymph node involvement, and presence of distant 
metastases.101 The number of studies dedicated to the 
performance of imaging techniques in perihilar 
cholangiocarcinoma is small and their quality modest.102 
CT scan accuracy for the evaluation of the degree of bile 
duct involvement is 86% (95% CI 77–92) with sensitivity 
and speciﬁ city for portal vein involvement of 89% (80–94) 
and 92% (85–96), hepatic artery of 83% (63–94) and 93% 
(69–99), and lymph node involvement of 61% (28–86) and 
88% (74–95), respectively.102 CT scans frequently do not 
detect peritoneal metastases.103 MRI, similar to CT, can 
detect proximal to stricture bile duct dilatation and 
perihilar mass, but magnetic resonance cholangiography 
(MRC) adds another dimension to the study, better 
delineating extent of the bile duct lesion (ﬁ gure 4A, B, 
and D). MRI enhanced with MRC has 89% sensitivity and 
Figure 4: Imaging studies of a patient with perihilar cholangiocarcinoma of the left hepatic duct
Note prominent left hepatic duct dilatation with obstruction of the left hepatic duct system on the CT scan (A), 
MRI (B), endoscopic retrograde cholangiography (C), and magnetic resonance cholangiography (D); (D) also shows 
bilateral obstruction of the biliary system at the right and left hepatic bile duct conﬂ uence.
A B
C D
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76% accuracy.78 When treatment with liver transplantation 
is feasible, evaluation of perihilar cholangiocarcinoma 
with endoscopic ultrasonography should not be 
accompanied by tumour sampling because of the high risk 
of needle tract seeding, which precludes this potentially 
curative treatment.104,105 By contrast, ﬁ ne-needle aspiration 
of lymph node tissue can be a valuable aid in the diagnosis 
of advanced perihilar chol angiocarcinoma. The role of 
CA 19-9 in the diagnosis of perihilar cholangiocarcinoma 
does not diﬀ er from that for intrahepatic disease. The 
serum concentration of IgG4 should be obtained to rule 
out IgG4-related cholangiopathy.106 However, serum IgG4 
can also be increased in cholangiocarcinoma.107
Endoscopic retrograde cholangiography is an 
invaluable approach in the initial evaluation of the biliary 
tree (ﬁ gure 4C) and as a ﬁ rst therapeutic step. Delineation 
of the biliary anatomy with MRI/MRC or CT scan, or 
both, before cholangiography should guide the 
endoscopic approach. Presence of a dominant stricture 
with or without upstream biliary duct dilatation is an 
indication for cytological evaluation through biliary 
brushings (ﬁ gure 3B). The evaluation should be done 
with conventional cytological analysis and, if available, 
ﬂ uorescence in-situ hybridisation (FISH). Assessment of 
conventional cytology is compromised by inﬂ ammatory 
changes due to stenting and infection and the highly 
desmoplastic nature of perihilar cholangiocarcinomas. 
FISH analysis, which is based on detection of quantitative 
genetic chromosomal changes indicating aneusomy 
(chromosome pair imbalance), increases sensitivity of 
conventional cytology from 15% to 38–58%.69 Serial 
polysomy detected by FISH in patients with primary 
sclerosing cholangitis can identify a subgroup of patients 
at high risk of development of cholangiocarcinoma 
compared with patients without polysomy.108 FISH 
analysis can detect lesions up to 2·7 years before a 
tumour is apparent on imaging studies.108,109 Percutaneous 
transhepatic cholangiography (PTC) can assist in gaining 
access to strictures not amenable to endoscopic 
retrograde cholangiography. However, PTC is best used 
as an interim step with PTC-placed stent internalisation 
either simultaneously with the procedure or after tract 
maturation, in 2–4 weeks, to improve physiological bile 
ﬂ ow and minimise patient discomfort.
Surgical treatment and liver transplantation
A new proposed surgical staging system has been 
designed to guide the surgical plan and selection of 
patients who might beneﬁ t from surgery.101 The surgery 
is rather complex and often necessitates lobar hepatic 
and bile duct resection, regional lymphadenopathy, and 
Roux-en-Y hepaticojejunostomy. The surgical techniques 
become more sophisticated, and have been aided by the 
incorporation of extended lobectomy, vascular 
reconstruction, and preoperative portal vein embol-
isation.110–112 This ﬁ nal procedure promotes hypertrophy 
of the uncompromised liver lobe and increases liver 
remnant volume. The success of the approach is often 
dependent on vascular anatomy.113 Portal vein ligation 
and in-situ splitting of the liver, referred to as associating 
liver partition and portal vein ligation for staged 
hepatectomy, promotes rapid liver regeneration and was 
newly introduced for the “small-for-size” setting.110 
However, this technique is associated with substantial 
morbidity and mortality and needs further evaluation. 
Positive regional lymph nodes (ie, cystic, pericholedochal, 
hepatic arterial, portal, and posterior pancreaticoduodenal) 
are no longer an absolute contraindication to surgical 
resection but, understandably, are associated with less 
favourable outcomes compared with patients with 
negative lymph nodes.69,114
The role of biliary tract stenting immediately before 
surgery is still the subject of debate.115 In patients with 
inoperable disease, drainage of 50% or more of the liver 
parenchyma can improve patient survival,116,117 but bilateral 
biliary stents can also predispose to stent-related 
complications, including infectious cholangitis.118 Despite 
misperceptions, covered self-expandable metal stents do 
not preclude either further surgery or radiotherapy. 
Before the treatment plan is ﬁ nalised, plastic biliary or 
covered self-expandable metal stents should be used. 
Covered stents prevent tumour ingrowth, but might 
migrate and are associated with increased rates of acute 
cholecystitis and pancreatitis.119–122 Placement of uncovered 
self-expandable metal stents, which can be dilated or 
stented in the future but cannot be removed, is a palliative 
option. As a rule of thumb, any patient with a biliary stent 
or stents in place and symptoms suggestive of acute 
infection should be promptly started on antibiotics 
providing coverage for Gram-negative microorganisms 
and be seen for stent re-evaluation and possible exchange.
Liver transplantation with neoadjuvant chemoradiation 
is the approach associated with the best outcomes in this 
lethal disease; however, only a few patients meet criteria 
for this option. The inclusion criteria include unresectable 
perihilar cholangiocarcinoma 3 cm or less in radial 
diameter without intrahepatic or extrahepatic 
metastases.123 The 5-year recurrence-free survival rate is 
similar to that for other widely accepted indications for 
liver transplantation at 68%.124 Patients with perihilar 
cholangiocarcinoma complicating primary sclerosing 
cholangitis should be treated, when possible, with liver 
transplantation, which will address the oncogenic ﬁ eld 
defect and underlying chronic progressive liver disease 
and negate potential complications from surgery in 
patients with advanced parenchymal liver disease (eg, 
portal hypertension). The notion of a neoplastic ﬁ eld 
defect in primary sclerosing cholangitis refers to the 
process in which chronic exposure of the biliary 
epithelium to oncogenic stimuli leads to ﬁ eld 
cancerisation. This idea is supported by frequent ﬁ ndings 
of synchronous biliary dysplastic lesions in liver explants 
of patients with primary sclerosing cholangitis who were 
diagnosed with cholangiocarcinoma.125
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Treatment for advanced disease
When a patient is not eligible for surgery or liver 
transplantation, chemotherapy with a gemcitabine and 
cisplatin combination can be considered. However, in 
the ABC-02 trial63 the eﬃ  cacy of this combination was 
not signiﬁ cantly diﬀ erent from that of gemcitabine alone 
in patients with perihilar cholangiocarcinoma; therefore, 
a practice standard of care has not been established for 
this subtype of cholangiocarcinoma. Proper preparation 
for chemotherapy includes biliary stenting. If palliative 
therapy is the goal of treatment and life expectancy is 
beyond 4–6 months, metal stents provide better 
durability, subject patients to less frequent invasive 
procedures, and are more cost-eﬀ ective compared with 
plastic stents.126–128 Beneﬁ ts of metal stents versus plastic 
stents and bilateral versus unilateral stents have been 
shown in maintenance of biliary patency.129 Metal stents 
have also been reported to improve survival compared 
with plastic stents (146 days and 49 days, respectively).130 
Endoscopic intraductal radiofrequency ablation is 
another feasible palliative option with acceptable 
complication rates and is currently under development.131
Metastatic cholangiocarcinoma
The most common route for intrahepatic cholangio-
carcinoma dissemination is intrahepatic involving the 
venous system. Spreading through the lymphatic system 
or along the biliary lumen is also reported. Perihilar 
cholangiocarcinoma usually metastasises through the 
lymphatic system. High tumour expression of VEGF is 
associated with intrahepatic metastases and EGFR 
overexpression with perineural invasion and lymphatic 
vessel invasion in intrahepatic cholangiocarcinoma.132 
Stromal cells and their secreted extracellular proteins are 
crucial for establishing the metastatic niche.133 In an 
animal model of cholangiocarcinoma, a Smac mimetic 
was shown to prevent extrahepatic metastases.134 Presence 
of metastases in cholangiocarcinoma is one of the main 
determinants of therapy, and patients with metastatic 
disease should be considered for systemic chemotherapy 
with gemcitabine and cisplatin.
Future directions
Continued dissection of the molecular pathways driving 
cholangiocarcinoma progression will focus our eﬀ orts on 
an individualised medicine approach for this cancer when 
advanced or in the adjuvant setting. Recent work 
examining risk factors for the development of intrahepatic 
cholangiocarcinoma emphasises the association between 
metformin use and a reduction in incidence of this disease 
in patients with diabetes.135 This ﬁ nding is biologically 
plausible because the mTOR signalling pathway, which is 
a target of metformin pharmacologically, is part of the 
cholangiocarcinoma oncogenic network. Thus, metformin 
use might be chemopreventive and calls for prospective 
studies, especially if a high-risk group can be identiﬁ ed 
(eg, a genetically high-risk population with primary 
sclerosing cholangitis). Another new direction is to 
approach tumour treatment in the context of its 
microenvironment. The stroma encompassing tumour 
can no longer be regarded as a barrier to tumour 
progression, but rather a crucial component governing 
tumour development and progression. Speciﬁ cally, 
evidence is growing for the role of cancer-associated 
ﬁ broblasts (CAFs) in tumour advancement, metastases, 
and chemoresistance.136 Tumour expression of α-SMA, the 
hallmark of CAFs, was negatively associated with survival 
of patients with intrahepatic cholangiocarcinoma. Active 
cross-talk between the tumour microenvironment and 
CAFs involves paracrine and autocrine signalling through 
modulation of growth factors and developmental (ie, 
Hedgehog) pathways.136 Targeting of CAFs could be an 
additional focus for development of new therapies and 
success of this approach was reported in a preclinical 
model using the BH3 mimetic, navitoclax.137 Further 
improvement of the currently available animal models of 
cholangiocarcinoma138 will be beneﬁ cial.
Identiﬁ cation of new tumour biomarkers in biological 
specimens is another important future direction. Genetic 
signatures for cholangiocarcinoma in serum, bile, or 
stool, similar to DNA stool testing for pancreatic cancer,139 
need to be evaluated. Bile specimen examination with 
cytology and development of more speciﬁ c diagnostic 
batteries using advanced technologies (ie, electrospray 
ionisation tandem mass spectrometry, two-dimensional 
gel electrophoresis, surface-enhanced laser desorption or 
ionisation, protein chips, and proteome analysis) might 
also be informative. These studies should be strengthened 
by elucidation of the role of the biomarkers in tumour 
biology (ie, the role of miRNAs in cholangiocarcinoma 
biology).140,141 The quality process for sample acquisition, 
processing, and interpretation needs to be standardised. 
In the near future we might be able to oﬀ er our patients 
an individualised therapy based on the driver mutation for 
their particular cancer and practise precision medicine.
Contributors
NR contributed to outline and drafting of the Seminar, critical revision, 
and important intellectual content. GJG contributed to the outline of the 
Seminar, critical revision for important intellectual content, and 
provided writing supervision.
Conﬂ icts of interest
We declare that we have no conﬂ icts of interest.
Acknowledgments
This work was supported by US National Institutes of Health grants 
DK59427 (GJG) and T32 DK007198 (NR), and the Mayo Foundation. We 
thank Konstantinos Lazaridis for contributing to the discussion of 
cholangiocarcinoma treatment in the context of personalised medicine, 
and Courtney Hoover for secretarial support.
References
1 Razumilava N, Gores GJ. Combination of gemcitabine and cisplatin 
for biliary tract cancer: a platform to build on. J Hepatol 2011; 
54: 577–78.
2 Nakanuma Y, Sato Y, Harada K, Sasaki M, Xu J, Ikeda H. 
Pathological classiﬁ cation of intrahepatic cholangiocarcinoma based 
on a new concept. World J Hepatol 2010; 2: 419–27.
3 Blechacz B, Gores GJ. Cholangiocarcinoma: advances in 
pathogenesis, diagnosis, and treatment. Hepatology 2008; 48: 308–21.
Seminar
www.thelancet.com   Vol 383   June 21, 2014 2177
4 DeOliveira ML, Cunningham SC, Cameron JL, et al. 
Cholangiocarcinoma: thirty-one-year experience with 564 patients at 
a single institution. Ann Surg 2007; 245: 755–62.
5 Komuta M, Govaere O, Vandecaveye V, et al. Histological diversity 
in cholangiocellular carcinoma reﬂ ects the diﬀ erent cholangiocyte 
phenotypes. Hepatology 2012; 55: 1876–88.
6 Roskams T. Liver stem cells and their implication in hepatocellular 
and cholangiocarcinoma. Oncogene 2006; 25: 3818–22.
7 Akiba J, Nakashima O, Hattori S, et al. Clinicopathologic analysis 
of combined hepatocellular-cholangiocarcinoma according to the 
latest WHO classiﬁ cation. Am J Surg Pathol 2013; 37: 496–505.
8 Khan SA, Emadossadaty S, Ladep NG, et al. Rising trends in 
cholangiocarcinoma: is the ICD classiﬁ cation system misleading 
us? J Hepatol 2012; 56: 848–54.
9 McLean L, Patel T. Racial and ethnic variations in the epidemiology 
of intrahepatic cholangiocarcinoma in the United States. Liver Int 
2006; 26: 1047–53.
10 Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. 
Hepatology 2011; 54: 173–84.
11 Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. 
Semin Liver Dis 2004; 24: 115–25.
12 Everhart JE, Ruhl CE. Burden of digestive diseases in the United 
States Part III: liver, biliary tract, and pancreas. Gastroenterology 
2009; 136: 1134–44.
13 Khan SA, Davidson BR, Goldin RD, et al, and the British Society of 
Gastroenterology. Guidelines for the diagnosis and treatment of 
cholangiocarcinoma: an update. Gut 2012; 61: 1657–69.
14 Welzel TM, Mellemkjaer L, Gloria G, et al. Risk factors for 
intrahepatic cholangiocarcinoma in a low-risk population: 
a nationwide case-control study. Int J Cancer 2007; 120: 638–41.
15 Donato F, Gelatti U, Tagger A, et al. Intrahepatic 
cholangiocarcinoma and hepatitis C and B virus infection, alcohol 
intake, and hepatolithiasis: a case-control study in Italy. 
Cancer Causes Control 2001; 12: 959–64.
16 El-Serag HB, Engels EA, Landgren O, et al. Risk of hepatobiliary and 
pancreatic cancers after hepatitis C virus infection: a population-based 
study of U.S. veterans. Hepatology 2009; 49: 116–23.
17 Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA. 
Risk factors of intrahepatic cholangiocarcinoma in the United 
States: a case-control study. Gastroenterology 2005; 128: 620–26.
18 Lee TY, Lee SS, Jung SW, et al. Hepatitis B virus infection and 
intrahepatic cholangiocarcinoma in Korea: a case-control study. 
Am J Gastroenterol 2008; 103: 1716–20.
19 Zhou YM, Yin ZF, Yang JM, et al. Risk factors for intrahepatic 
cholangiocarcinoma: a case-control study in China. 
World J Gastroenterol 2008; 14: 632–35.
20 Sekiya S, Suzuki A. Intrahepatic cholangiocarcinoma can arise from 
Notch-mediated conversion of hepatocytes. J Clin Invest 2012; 
122: 3914–18.
21 Yamamoto S, Kubo S, Hai S, et al. Hepatitis C virus infection as a 
likely etiology of intrahepatic cholangiocarcinoma. Cancer Sci 2004; 
95: 592–95.
22 Palmer WC, Patel T. Are common factors involved in the 
pathogenesis of primary liver cancers? A meta-analysis of risk factors 
for intrahepatic cholangiocarcinoma. J Hepatol 2012; 57: 69–76.
23 Chapman MH, Webster GJ, Bannoo S, Johnson GJ, Wittmann J, 
Pereira SP. Cholangiocarcinoma and dominant strictures in 
patients with primary sclerosing cholangitis: a 25-year single-centre 
experience. Eur J Gastroenterol Hepatol 2012; 24: 1051–58.
24 Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic 
malignancies in primary sclerosing cholangitis. J Hepatol 2002; 
36: 321–27.
25 Chapman R, Fevery J, Kalloo A, et al, and the American Association 
for the Study of Liver Diseases. Diagnosis and management of 
primary sclerosing cholangitis. Hepatology 2010; 51: 660–78.
26 Claessen MM, Vleggaar FP, Tytgat KM, Siersema PD, 
van Buuren HR. High lifetime risk of cancer in primary sclerosing 
cholangitis. J Hepatol 2009; 50: 158–64.
27 Boberg KM, Bergquist A, Mitchell S, et al. Cholangiocarcinoma in 
primary sclerosing cholangitis: risk factors and clinical 
presentation. Scand J Gastroenterol 2002; 37: 1205–11.
28 Chalasani N, Baluyut A, Ismail A, et al. Cholangiocarcinoma in 
patients with primary sclerosing cholangitis: a multicenter 
case-control study. Hepatology 2000; 31: 7–11.
29 European Association for the Study of the Liver. EASL clinical 
practice guidelines: management of cholestatic liver diseases. 
J Hepatol 2009; 51: 237–67.
30 Razumilava N, Gores GJ, Lindor KD. Cancer surveillance in 
patients with primary sclerosing cholangitis. Hepatology 2011; 
54: 1842–52.
31 Söreide K, Körner H, Havnen J, Söreide JA. Bile duct cysts in 
adults. Br J Surg 2004; 91: 1538–48.
32 Kaewpitoon N, Kaewpitoon SJ, Pengsaa P, Sripa B. 
Opisthorchis viverrini: the carcinogenic human liver ﬂ uke. 
World J Gastroenterol 2008; 14: 666–74.
33 Shin HR, Lee CU, Park HJ, et al. Hepatitis B and C virus, 
Clonorchis sinensis for the risk of liver cancer: a case-control study in 
Pusan, Korea. Int J Epidemiol 1996; 25: 933–40.
34 Honjo S, Srivatanakul P, Sriplung H, et al. Genetic and 
environmental determinants of risk for cholangiocarcinoma via 
Opisthorchis viverrini in a densely infested area in Nakhon Phanom, 
northeast Thailand. Int J Cancer 2005; 117: 854–60.
35 Huang MH, Chen CH, Yen CM, et al. Relation of hepatolithiasis to 
helminthic infestation. J Gastroenterol Hepatol 2005; 20: 141–46.
36 Tocchi A, Mazzoni G, Liotta G, Lepre L, Cassini D, Miccini M. Late 
development of bile duct cancer in patients who had biliary-enteric 
drainage for benign disease: a follow-up study of more than 
1000 patients. Ann Surg 2001; 234: 210–14.
37 Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, 
McGlynn KA. Metabolic syndrome increases the risk of primary 
liver cancer in the United States: a study in the SEER-Medicare 
database. Hepatology 2011; 54: 463–71.
38 Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, 
Kinzler KW. Cancer genome landscapes. Science 2013; 339: 1546–58.
39 Zabron A, Edwards RJ, Khan SA. The challenge of 
cholangiocarcinoma: dissecting the molecular mechanisms of an 
insidious cancer. Dis Model Mech 2013; 6: 281–92.
40 Sia D, Hoshida Y, Villanueva A, et al. Integrative molecular analysis 
of intrahepatic cholangiocarcinoma reveals 2 classes that have 
diﬀ erent outcomes. Gastroenterology 2013; 144: 829–40.
41 Sansone P, Bromberg J. Targeting the interleukin-6/Jak/stat 
pathway in human malignancies. J Clin Oncol 2012; 30: 1005–14.
42 Andersen JB, Spee B, Blechacz BR, et al. Genomic and genetic 
characterization of cholangiocarcinoma identiﬁ es therapeutic 
targets for tyrosine kinase inhibitors. Gastroenterology 2012; 
142: 1021–31 e15.
43 Han W, Lo HW. Landscape of EGFR signaling network in human 
cancers: biology and therapeutic response in relation to receptor 
subcellular locations. Cancer Lett 2012; 318: 124–34.
44 Geynisman DM, Catenacci DV. Toward personalized treatment of 
advanced biliary tract cancers. Discov Med 2012; 14: 41–57.
45 Ong CK, Subimerb C, Pairojkul C, et al. Exome sequencing of liver 
ﬂ uke-associated cholangiocarcinoma. Nat Genet 2012; 44: 690–93.
46 Chung JY, Hong SM, Choi BY, Cho H, Yu E, Hewitt SM. The 
expression of phospho-AKT, phospho-mTOR, and PTEN in 
extrahepatic cholangiocarcinoma. Clin Cancer Res 2009; 15: 660–67.
47 Lee D, Do IG, Choi K, et al. The expression of phospho-AKT1 and 
phospho-MTOR is associated with a favorable prognosis 
independent of PTEN expression in intrahepatic 
cholangiocarcinomas. Mod Pathol 2012; 25: 131–39.
48 Wu YM, Su F, Kalyana-Sundaram S, et al. Identiﬁ cation of 
targetable FGFR gene fusions in diverse cancers. Cancer Discov 
2013; 3: 636–47.
49 Hofmann JJ, Zovein AC, Koh H, Radtke F, Weinmaster G, 
Iruela-Arispe ML. Jagged1 in the portal vein mesenchyme regulates 
intrahepatic bile duct development: insights into Alagille syndrome. 
Development 2010; 137: 4061–72.
50 Fan B, Malato Y, Calvisi DF, et al. Cholangiocarcinomas can 
originate from hepatocytes in mice. J Clin Invest 2012; 122: 2911–15.
51 Dill MT, Tornillo L, Fritzius T, et al. Constitutive Notch2 signaling 
induces hepatic tumors in mice. Hepatology 2013; 57: 1607–19.
52 Berman DM, Karhadkar SS, Maitra A, et al. Widespread 
requirement for Hedgehog ligand stimulation in growth of 
digestive tract tumours. Nature 2003; 425: 846–51.
53 Jinawath A, Akiyama Y, Sripa B, Yuasa Y. Dual blockade of the 
Hedgehog and ERK1/2 pathways coordinately decreases 
proliferation and survival of cholangiocarcinoma cells. 
J Cancer Res Clin Oncol 2007; 133: 271–78.
Seminar
2178 www.thelancet.com   Vol 383   June 21, 2014
54 El Khatib M, Kalnytska A, Palagani V, et al. Inhibition of hedgehog 
signaling attenuates carcinogenesis in vitro and increases necrosis 
of cholangiocellular carcinoma. Hepatology 2013; 57: 1035–45.
55 Razumilava N, Bronk SF, Smoot RL, et al. miR-25 targets 
TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 
and promotes apoptosis resistance in cholangiocarcinoma. 
Hepatology 2012; 55: 465–75.
56 Fingas CD, Bronk SF, Werneburg NW, et al. Myoﬁ broblast-derived 
PDGF-BB promotes Hedgehog survival signaling in 
cholangiocarcinoma cells. Hepatology 2011; 54: 2076–88.
57 Borger DR, Tanabe KK, Fan KC, et al. Frequent mutation of 
isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma 
identiﬁ ed through broad-based tumor genotyping. Oncologist 2012; 
17: 72–79.
58 Wang P, Dong Q, Zhang C, et al. Mutations in isocitrate 
dehydrogenase 1 and 2 occur frequently in intrahepatic 
cholangiocarcinomas and share hypermethylation targets with 
glioblastomas. Oncogene 2013; 32: 3091–100.
59 Kipp BR, Voss JS, Kerr SE, et al. Isocitrate dehydrogenase 1 and 2 
mutations in cholangiocarcinoma. Hum Pathol 2012; 43: 1552–58.
60 Reitman ZJ, Parsons DW, Yan H. IDH1 and IDH2: not your typical 
oncogenes. Cancer Cell 2010; 17: 215–16.
61 Rohle D, Popovici-Muller J, Palaskas N, et al. An inhibitor of mutant 
IDH1 delays growth and promotes diﬀ erentiation of glioma cells. 
Science 2013; 340: 626–30.
62 Wang F, Travins J, DeLaBarre B, et al. Targeted inhibition of mutant 
IDH2 in leukemia cells induces cellular diﬀ erentiation. Science 
2013; 340: 622–26.
63 Valle J, Wasan H, Palmer DH, et al, and the ABC-02 Trial 
Investigators. Cisplatin plus gemcitabine versus gemcitabine for 
biliary tract cancer. N Engl J Med 2010; 362: 1273–81.
64 Hezel AF, Deshpande V, Zhu AX. Genetics of biliary tract cancers 
and emerging targeted therapies. J Clin Oncol 2010; 28: 3531–40.
65 Lee J, Park SH, Chang HM, et al. Gemcitabine and oxaliplatin with 
or without erlotinib in advanced biliary-tract cancer: a multicentre, 
open-label, randomised, phase 3 study. Lancet Oncol 2012; 13: 181–88.
66 Sia D, Tovar V, Moeini A, Llovet JM. Intrahepatic 
cholangiocarcinoma: pathogenesis and rationale for molecular 
therapies. Oncogene 2013; 32: 4861–70.
67 Yamasaki S. Intrahepatic cholangiocarcinoma: macroscopic type 
and stage classiﬁ cation. J Hepatobiliary Pancreat Surg 2003; 
10: 288–91.
68 Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis 
and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 
2011; 8: 512–22.
69 Razumilava N, Gores GJ. Classiﬁ cation, diagnosis, and 
management of cholangiocarcinoma. Clin Gastroenterol Hepatol 
2013; 11: 13–21 e1.
70 Rimola J, Forner A, Reig M, et al. Cholangiocarcinoma in cirrhosis: 
absence of contrast washout in delayed phases by magnetic 
resonance imaging avoids misdiagnosis of hepatocellular 
carcinoma. Hepatology 2009; 50: 791–98.
71 Iavarone M, Piscaglia F, Vavassori S, et al. Contrast enhanced 
CT-scan to diagnose intrahepatic cholangiocarcinoma in patients 
with cirrhosis. J Hepatol 2013; 58: 1188–93.
72 Kim SH, Lee CH, Kim BH, et al. Typical and atypical imaging 
ﬁ ndings of intrahepatic cholangiocarcinoma using gadolinium 
ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic 
resonance imaging. J Comput Assist Tomogr 2012; 36: 704–09.
73 Hwang J, Kim YK, Park MJ, et al. Diﬀ erentiating combined 
hepatocellular and cholangiocarcinoma from mass-forming 
intrahepatic cholangiocarcinoma using gadoxetic acid-enhanced 
MRI. J Magn Reson Imaging 2012; 36: 881–89.
74 Chong YS, Kim YK, Lee MW, et al. Diﬀ erentiating mass-forming 
intrahepatic cholangiocarcinoma from atypical hepatocellular 
carcinoma using gadoxetic acid-enhanced MRI. Clin Radiol 2012; 
67: 766–73.
75 Lan BY, Kwee SA, Wong LL. Positron emission tomography in 
hepatobiliary and pancreatic malignancies: a review. Am J Surg 
2012; 204: 232–41.
76 Anderson CD, Rice MH, Pinson CW, Chapman WC, Chari RS, 
Delbeke D. Fluorodeoxyglucose PET imaging in the evaluation of 
gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg 
2004; 8: 90–97.
77 Galassi M, Iavarone M, Rossi S, et al. Patterns of appearance and 
risk of misdiagnosis of intrahepatic cholangiocarcinoma in 
cirrhosis at contrast enhanced ultrasound. Liver Int 2013; 
33: 771–79.
78 Charatcharoenwitthaya P, Enders FB, Halling KC, Lindor KD. 
Utility of serum tumor markers, imaging, and biliary cytology for 
detecting cholangiocarcinoma in primary sclerosing cholangitis. 
Hepatology 2008; 48: 1106–17.
79 Levy C, Lymp J, Angulo P, Gores GJ, Larusso N, Lindor KD. The 
value of serum CA 19-9 in predicting cholangiocarcinomas in 
patients with primary sclerosing cholangitis. Dig Dis Sci 2005; 
50: 1734–40.
80 Venkatesh PG, Navaneethan U, Shen B, McCullough AJ. Increased 
serum levels of carbohydrate antigen 19-9 and outcomes in primary 
sclerosing cholangitis patients without cholangiocarcinoma. 
Dig Dis Sci 2013; 58: 850–57.
81 Sinakos E, Saenger AK, Keach J, Kim WR, Lindor KD. Many 
patients with primary sclerosing cholangitis and increased serum 
levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma. 
Clin Gastroenterol Hepatol 2011; 9: 434–9 e1.
82 Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ. The utility 
of CA 19-9 in the diagnoses of cholangiocarcinoma in patients 
without primary sclerosing cholangitis. Am J Gastroenterol 2000; 
95: 204–07.
83 Nehls O, Gregor M, Klump B. Serum and bile markers for 
cholangiocarcinoma. Semin Liver Dis 2004; 24: 139–54.
84 Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarcinoma: 
rising frequency, improved survival, and determinants of outcome 
after resection. Ann Surg 2008; 248: 84–96.
85 Li YY, Li H, Lv P, et al. Prognostic value of cirrhosis for intrahepatic 
cholangiocarcinoma after surgical treatment. J Gastrointest Surg 
2011; 15: 608–13.
86 Sapisochin G, Fidelman N, Roberts JP, Yao FY. Mixed hepatocellular 
cholangiocarcinoma and intrahepatic cholangiocarcinoma in 
patients undergoing transplantation for hepatocellular carcinoma. 
Liver Transpl 2011; 17: 934–42.
87 Kim JH, Won HJ, Shin YM, Kim KA, Kim PN. Radiofrequency 
ablation for the treatment of primary intrahepatic 
cholangiocarcinoma. AJR Am J Roentgenol 2011; 196: W205-9.
88 Xu HX, Wang Y, Lu MD, Liu LN. Percutaneous ultrasound-guided 
thermal ablation for intrahepatic cholangiocarcinoma. Br J Radiol 
2012; 85: 1078–84.
89 Kiefer MV, Albert M, McNally M, et al. Chemoembolization of 
intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, 
mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study. 
Cancer 2011; 117: 1498–505.
90 Park SY, Kim JH, Yoon HJ, Lee IS, Yoon HK, Kim KP. Transarterial 
chemoembolization versus supportive therapy in the palliative 
treatment of unresectable intrahepatic cholangiocarcinoma. 
Clin Radiol 2011; 66: 322–28.
91 Vogl TJ, Naguib NN, Nour-Eldin NE, et al. Transarterial 
chemoembolization in the treatment of patients with unresectable 
cholangiocarcinoma: results and prognostic factors governing 
treatment success. Int J Cancer 2012; 131: 733–40.
92 Shen WF, Zhong W, Liu Q, Sui CJ, Huang YQ, Yang JM. Adjuvant 
transcatheter arterial chemoembolization for intrahepatic 
cholangiocarcinoma after curative surgery: retrospective control 
study. World J Surg 2011; 35: 2083–91.
93 Kuhlmann JB, Euringer W, Spangenberg HC, et al. Treatment of 
unresectable cholangiocarcinoma: conventional transarterial 
chemoembolization compared with drug eluting bead-transarterial 
chemoembolization and systemic chemotherapy. 
Eur J Gastroenterol Hepatol 2012; 24: 437–43.
94 Hoﬀ mann RT, Paprottka PM, Schön A, et al. Transarterial hepatic 
yttrium-90 radioembolization in patients with unresectable 
intrahepatic cholangiocarcinoma: factors associated with prolonged 
survival. Cardiovasc Intervent Radiol 2012; 35: 105–16.
95 Raﬁ  S, Piduru SM, El-Rayes B, et al. Yttrium-90 radioembolization 
for unresectable standard-chemorefractory intrahepatic 
cholangiocarcinoma: survival, eﬃ  cacy, and safety study. 
Cardiovasc Intervent Radiol 2013; 36: 440–48.
96 Kopek N, Holt MI, Hansen AT, Høyer M. Stereotactic body 
radiotherapy for unresectable cholangiocarcinoma. Radiother Oncol 
2010; 94: 47–52.
Seminar
www.thelancet.com   Vol 383   June 21, 2014 2179
97 Barney BM, Olivier KR, Miller RC, Haddock MG. Clinical outcomes 
and toxicity using stereotactic body radiotherapy (SBRT) for 
advanced cholangiocarcinoma. Radiat Oncol 2012; 7: 67.
98 Polistina FA, Guglielmi R, Baiocchi C, et al. Chemoradiation 
treatment with gemcitabine plus stereotactic body radiotherapy for 
unresectable, non-metastatic, locally advanced hilar 
cholangiocarcinoma. Results of a ﬁ ve year experience. 
Radiother Oncol 2011; 99: 120–23.
99 Katabi N, Torres J, Klimstra DS. Intraductal tubular neoplasms of 
the bile ducts. Am J Surg Pathol 2012; 36: 1647–55.
100 Nagorney DM, Donohue JH, Farnell MB, Schleck CD, Ilstrup DM. 
Outcomes after curative resections of cholangiocarcinoma. 
Arch Surg 1993; 128: 871–77.
101 Deoliveira ML, Schulick RD, Nimura Y, et al. New staging system 
and a registry for perihilar cholangiocarcinoma. Hepatology 2011; 
53: 1363–71.
102 Ruys AT, van Beem BE, Engelbrecht MR, Bipat S, Stoker J, 
Van Gulik TM. Radiological staging in patients with hilar 
cholangiocarcinoma: a systematic review and meta-analysis. 
Br J Radiol 2012; 85: 1255–62.
103 Vilgrain V. Staging cholangiocarcinoma by imaging studies. HPB 
(Oxford) 2008; 10: 106–09.
104 Heimbach JK, Sanchez W, Rosen CB, Gores GJ. Trans-peritoneal ﬁ ne 
needle aspiration biopsy of hilar cholangiocarcinoma is associated 
with disease dissemination. HPB (Oxford) 2011; 13: 356–60.
105 Levy MJ, Heimbach JK, Gores GJ. Endoscopic ultrasound staging of 
cholangiocarcinoma. Curr Opin Gastroenterol 2012; 28: 244–52.
106 Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med 
2012; 366: 539–51.
107 Oseini AM, Chaiteerakij R, Shire AM, et al. Utility of serum 
immunoglobulin G4 in distinguishing immunoglobulin G4-associated 
cholangitis from cholangiocarcinoma. Hepatology 2011; 54: 940–48.
108 Barr Fritcher EG, Kipp BR, Voss JS, et al. Primary sclerosing 
cholangitis patients with serial polysomy ﬂ uorescence in situ 
hybridization results are at increased risk of cholangiocarcinoma. 
Am J Gastroenterol 2011; 106: 2023–28.
109 Gonda TA, Glick MP, Sethi A, et al. Polysomy and p16 deletion by 
ﬂ uorescence in situ hybridization in the diagnosis of indeterminate 
biliary strictures. Gastrointest Endosc 2012; 75: 74–79.
110 Schnitzbauer AA, Lang SA, Goessmann H, et al. Right portal vein 
ligation combined with in situ splitting induces rapid left lateral 
liver lobe hypertrophy enabling 2-staged extended right hepatic 
resection in small-for-size settings. Ann Surg 2012; 255: 405–14.
111 Hemming AW, Mekeel K, Khanna A, Baquerizo A, Kim RD. Portal 
vein resection in management of hilar cholangiocarcinoma. 
J Am Coll Surg 2011; 212: 604–13.
112 Hong YK, Choi SB, Lee KH, et al. The eﬃ  cacy of portal vein 
embolization prior to right extended hemihepatectomy for hilar 
cholangiocellular carcinoma: a retrospective cohort study. 
Eur J Surg Oncol 2011; 37: 237–44.
113 Mouly C, Fuks D, Browet F, et al. Feasibility of the Glissonian 
approach during right hepatectomy. HPB (Oxford) 2013; 15: 638–45.
114 Nagorney DM, Kendrick ML. Hepatic resection in the treatment of 
hilar cholangiocarcinoma. Adv Surg 2006; 40: 159–71.
115 van der Gaag NA, Rauws EA, van Eijck CH, et al. Preoperative 
biliary drainage for cancer of the head of the pancreas. N Engl J Med 
2010; 362: 129–37.
116 Deviere J, Baize M, de Toeuf J, Cremer M. Long-term follow-up of 
patients with hilar malignant stricture treated by endoscopic 
internal biliary drainage. Gastrointest Endosc 1988; 34: 95–101.
117 Vienne A, Hobeika E, Gouya H, et al. Prediction of drainage 
eﬀ ectiveness during endoscopic stenting of malignant hilar 
strictures: the role of liver volume assessment. Gastrointest Endosc 
2010; 72: 728–35.
118 Chang WH, Kortan P, Haber GB. Outcome in patients with 
bifurcation tumors who undergo unilateral versus bilateral hepatic 
duct drainage. Gastrointest Endosc 1998; 47: 354–62.
119 Krokidis M, Fanelli F, Orgera G, Bezzi M, Passariello R, 
Hatzidakis A. Percutaneous treatment of malignant jaundice due to 
extrahepatic cholangiocarcinoma: covered Viabil stent versus 
uncovered Wallstents. Cardiovasc Intervent Radiol 2010; 33: 97–106.
120 Kullman E, Frozanpor F, Söderlund C, et al. Covered versus 
uncovered self-expandable nitinol stents in the palliative treatment 
of malignant distal biliary obstruction: results from a randomized, 
multicenter study. Gastrointest Endosc 2010; 72: 915–23.
121 Kahaleh M, Tokar J, Conaway MR, et al. Eﬃ  cacy and complications 
of covered Wallstents in malignant distal biliary obstruction. 
Gastrointest Endosc 2005; 61: 528–33.
122 Isayama H, Komatsu Y, Tsujino T, et al. A prospective randomised 
study of “covered” versus “uncovered” diamond stents for the 
management of distal malignant biliary obstruction. Gut 2004; 
53: 729–34.
123 Rosen CB, Heimbach JK, Gores GJ. Liver transplantation for 
cholangiocarcinoma. Transpl Int 2010; 23: 692–97.
124 Darwish Murad S, Kim WR, Therneau T, et al. Predictors of 
pretransplant dropout and posttransplant recurrence in patients 
with perihilar cholangiocarcinoma. Hepatology 2012; 56: 972–81.
125 Lewis JT, Talwalkar JA, Rosen CB, Smyrk TC, Abraham SC. 
Precancerous bile duct pathology in end-stage primary sclerosing 
cholangitis, with and without cholangiocarcinoma. Am J Surg Pathol 
2010; 34: 27–34.
126 Raju RP, Jaganmohan SR, Ross WA, et al. Optimum palliation of 
inoperable hilar cholangiocarcinoma: comparative assessment of 
the eﬃ  cacy of plastic and self-expanding metal stents. Dig Dis Sci 
2011; 56: 1557–64.
127 Soderlund C, Linder S. Covered metal versus plastic stents for 
malignant common bile duct stenosis: a prospective, randomized, 
controlled trial. Gastrointest Endosc 2006; 63: 986–95.
128 Yeoh KG, Zimmerman MJ, Cunningham JT, Cotton PB. 
Comparative costs of metal versus plastic biliary stent strategies for 
malignant obstructive jaundice by decision analysis. 
Gastrointest Endosc 1999; 49: 466–71.
129 Liberato MJ, Canena JM. Endoscopic stenting for hilar 
cholangiocarcinoma: eﬃ  cacy of unilateral and bilateral placement 
of plastic and metal stents in a retrospective review of 480 patients. 
BMC Gastroenterol 2012; 12: 103.
130 Sangchan A, Kongkasame W, Pugkhem A, Jenwitheesuk K, 
Mairiang P. Eﬃ  cacy of metal and plastic stents in unresectable 
complex hilar cholangiocarcinoma: a randomized controlled trial. 
Gastrointest Endosc 2012; 76: 93–99.
131 Wadsworth CA, Westaby D, Khan SA. Endoscopic radiofrequency 
ablation for cholangiocarcinoma. Curr Opin Gastroenterol 2013; 
29: 305–11.
132 Yoshikawa D, Ojima H, Iwasaki M, et al. Clinicopathological and 
prognostic signiﬁ cance of EGFR, VEGF, and HER2 expression in 
cholangiocarcinoma. Br J Cancer 2008; 98: 418–25.
133 Erez N. Cancer: angiogenic awakening. Nature 2013; 500: 37–38.
134 Fingas CD, Blechacz BR, Smoot RL, et al. A smac mimetic reduces 
TNF related apoptosis inducing ligand (TRAIL)-induced invasion 
and metastasis of cholangiocarcinoma cells. Hepatology 2010; 
52: 550–61.
135 Chaiteerakij R, Yang JD, Harmsen WS, et al. Risk factors for 
intrahepatic cholangiocarcinoma: association between metformin 
use and reduced cancer risk. Hepatology 2013; 57: 648–55.
136 Sirica AE. The role of cancer-associated myoﬁ broblasts in 
intrahepatic cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 
2012; 9: 44–54.
137 Mertens JC, Fingas CD, Christensen JD, et al. Therapeutic eﬀ ects of 
deleting cancer-associated ﬁ broblasts in cholangiocarcinoma. 
Cancer Res 2013; 73: 897–907.
138 Ko KS, Peng J, Yang H. Animal models of cholangiocarcinoma. 
Curr Opin Gastroenterol 2013; 29: 312–18.
139 Kisiel JB, Yab TC, Taylor WR, et al. Stool DNA testing for the 
detection of pancreatic cancer: assessment of methylation marker 
candidates. Cancer 2012; 118: 2623–31.
140 Ishida M, Selaru FM. miRNA-based therapeutic strategies. 
Curr Anesthesiol Rep 2013; 1: 63–70.
141 Takahashi K, Yan I, Wen HJ, Patel T. microRNAs in liver disease: 
from diagnostics to therapeutics. Clin Biochem 2013; 46: 946–52.
